{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T12:26:32Z","timestamp":1768566392998,"version":"3.49.0"},"reference-count":47,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the Program of the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82173604"],"award-info":[{"award-number":["82173604"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Objective<\/jats:title>\n<jats:p>This study aims to evaluate the efficacy and safety of JAK inhibitors in the treatment of patients with RA.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>The databases CNKI, VIP, Wanfang, CBM, and PubMed, Embase, Cochrane Library and Web of Science were searched to identify relevant randomized controlled trials (RCTs), all from the time of database creation to April 2024. Screening, data extraction, and risk of bias assessment (using Review Manager-5.3 software) were independently performed by at least two authors. The network meta-analysis was conducted using R 4.1.3 software. PROSPERO registration number: CRD42022370444.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Thirty-three RCTs included 15,961 patients The experimental groups involved six JAK inhibitors (filgotinib, tofacitinib, decernotinib, baricitinib, upadacitinib and peficitinib) and 12 interventions (different doses of the six JAK inhibitors), and the control group involved adalimumab (ADA) and placebo. Compared with placebo, all JAK inhibitors showed a significant increase in efficacy measures (ACR20\/50\/70). Compared with ADA, only tofacitinib, low-dose decernotinib, and high-dose peficitinib showed a significant increase in ACR20\/50\/70. Decernotinib ranked first in the SUCRA ranking of ACR20\/50\/70. In terms of safety indicators, only those differences between low-dose filgotinib and high-dose upadacitinib, low-dose tofacitinib and high-dose upadacitinib were statistically significant. Low-dose filgotinib ranked first in the SUCRA ranking with adverse events as safety indicators. Only the efficacy and safety of tofacitinib ranked higher among different SUCRA rankings.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Six JAK inhibitors have better efficacy than placebo. The superior efficacy of decernotinib and safety of low-dose filgotinib can be found in the SUCRA. However, there are no significant differences in safety between the different JAK inhibitors. Head-to-head trials, directly comparing one against each other, are required to provide more certain evidence.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0305621","type":"journal-article","created":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T17:46:58Z","timestamp":1718992018000},"page":"e0305621","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":6,"title":["The efficacy and safety of different Janus kinase inhibitors as monotherapy in rheumatoid arthritis: A Bayesian network meta-analysis"],"prefix":"10.1371","volume":"19","author":[{"given":"Bingjia","family":"Qu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junyi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxin","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruobing","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5854-7007","authenticated-orcid":true,"given":"Lingyu","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2024,6,21]]},"reference":[{"key":"pone.0305621.ref001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2015.10.003","article-title":"Treatment of rheumatoid arthritis: Unraveling the conundrum","volume":"65","author":"E Zampeli","year":"2015","journal-title":"J Autoimmun"},{"issue":"12","key":"pone.0305621.ref002","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/rheumatology\/41.12.1367","article-title":"The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses.","volume":"41","author":"D Aletaha","year":"2002","journal-title":"Rheumatology (Oxford)."},{"issue":"2","key":"pone.0305621.ref003","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/art.38949","article-title":"A randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritis.","volume":"67","author":"RM Fleischmann","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"18","key":"pone.0305621.ref004","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1007\/s40265-017-0835-9","article-title":"Tofacitinib: A Review in Rheumatoid Arthritis.","volume":"77","author":"S. Dhillon","year":"2017","journal-title":"Drugs"},{"issue":"7","key":"pone.0305621.ref005","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis","volume":"376","author":"PC Taylor","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"pone.0305621.ref006","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1080\/14397595.2018.1553489","article-title":"Efficacy and safety of tofacitinib in Japanese patients with rheumatoid arthritis by background methotrexate dose: A post hoc analysis of clinical trial data.","volume":"29","author":"T Takeuchi","year":"2019","journal-title":"Mod Rheumatol."},{"issue":"13","key":"pone.0305621.ref007","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","article-title":"Baricitinib in Patients with Refractory Rheumatoid Arthritis","volume":"374","author":"MC Genovese","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"pone.0305621.ref008","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/art.40054","article-title":"Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis.","volume":"69","author":"MC Genovese","year":"2017","journal-title":"Arthritis Rheumatol."},{"issue":"11","key":"pone.0305621.ref009","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/art.41032","article-title":"Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial.","volume":"71","author":"R Fleischmann","year":"2019","journal-title":"Arthritis Rheumatol."},{"issue":"7","key":"pone.0305621.ref010","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1136\/annrheumdis-2020-219214","article-title":"Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial","volume":"80","author":"B Combe","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"pone.0305621.ref011","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"D Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"pone.0305621.ref012","first-page":"Ed000142","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions.","volume":"10","author":"M Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev."},{"issue":"20","key":"pone.0305621.ref013","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1002\/sim.1875","article-title":"Combination of direct and indirect evidence in mixed treatment comparisons.","volume":"23","author":"G Lu","year":"2004","journal-title":"Stat Med."},{"key":"pone.0305621.ref014","doi-asserted-by":"crossref","first-page":"c7086","DOI":"10.1136\/bmj.c7086","article-title":"Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis","volume":"342","author":"S Trelle","year":"2011","journal-title":"Bmj"},{"issue":"3","key":"pone.0305621.ref015","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/art.33383","article-title":"Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs.","volume":"64","author":"R Fleischmann","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"6","key":"pone.0305621.ref016","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"R Fleischmann","year":"2012","journal-title":"N Engl J Med"},{"issue":"4","key":"pone.0305621.ref017","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/art.33419","article-title":"A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone.","volume":"64","author":"JM Kremer","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"7","key":"pone.0305621.ref018","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1002\/art.24567","article-title":"The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo","volume":"60","author":"JM Kremer","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"8","key":"pone.0305621.ref019","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/acr.20494","article-title":"Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate.","volume":"63","author":"Y Tanaka","year":"2011","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"4","key":"pone.0305621.ref020","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3109\/14397595.2014.995875","article-title":"Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study.","volume":"25","author":"Y Tanaka","year":"2015","journal-title":"Mod Rheumatol."},{"issue":"6","key":"pone.0305621.ref021","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis","volume":"367","author":"RF van Vollenhoven","year":"2012","journal-title":"N Engl J Med"},{"issue":"25","key":"pone.0305621.ref022","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","article-title":"Tofacitinib versus methotrexate in rheumatoid arthritis","volume":"370","author":"EB Lee","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0305621.ref023","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/annrheumdis-2016-210094","article-title":"Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study","volume":"76","author":"M Dougados","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"pone.0305621.ref024","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1136\/annrheumdis-2014-206478","article-title":"Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate","volume":"74","author":"EC Keystone","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"pone.0305621.ref025","first-page":"732","article-title":"Baricitinib in patients with rheumatoid arthritis with inadequate response to methotrexate: results from a phase 3 study","volume":"38","author":"Z Li","year":"2020","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"pone.0305621.ref026","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3899\/jrheum.150613","article-title":"Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study.","volume":"43","author":"Y Tanaka","year":"2016","journal-title":"J Rheumatol"},{"issue":"4","key":"pone.0305621.ref027","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/art.39955","article-title":"Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate.","volume":"69","author":"AJ Kivitz","year":"2017","journal-title":"Arthritis Rheumatol."},{"issue":"6","key":"pone.0305621.ref028","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1136\/annrheumdis-2015-208279","article-title":"Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study.","volume":"75","author":"T Takeuchi","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"pone.0305621.ref029","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1136\/annrheumdis-2019-215164","article-title":"Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan.","volume":"78","author":"T Takeuchi","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"pone.0305621.ref030","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1136\/annrheumdis-2019-215163","article-title":"Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3).","volume":"78","author":"Y Tanaka","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"pone.0305621.ref031","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/art.39473","article-title":"VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis.","volume":"68","author":"MC Genovese","year":"2016","journal-title":"Arthritis Rheumatol."},{"issue":"4","key":"pone.0305621.ref032","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1001\/jama.2019.9055","article-title":"Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial.","volume":"322","author":"MC Genovese","year":"2019","journal-title":"JAMA"},{"issue":"6","key":"pone.0305621.ref033","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1136\/annrheumdis-2016-210105","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2).","volume":"76","author":"A Kavanaugh","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"pone.0305621.ref034","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1136\/annrheumdis-2016-210104","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1).","volume":"76","author":"R Westhovens","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"10139","key":"pone.0305621.ref035","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","article-title":"Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial.","volume":"391","author":"GR Burmester","year":"2018","journal-title":"The Lancet"},{"issue":"10139","key":"pone.0305621.ref036","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","article-title":"Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.","volume":"391","author":"MC Genovese","year":"2018","journal-title":"The Lancet"},{"issue":"11","key":"pone.0305621.ref037","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1093\/rheumatology\/keaa084","article-title":"Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb\/III study.","volume":"59","author":"H Kameda","year":"2020","journal-title":"Rheumatology (Oxford)."},{"issue":"6","key":"pone.0305621.ref038","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1136\/annrheumdis-2020-219213","article-title":"Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial","volume":"80","author":"R Westhovens","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"pone.0305621.ref039","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanwpc.2023.100925","article-title":"Safety and efficacy of peficitinib in Asian patients with rheumatoid arthritis who had an inadequate response or intolerance to methotrexate: results of a multicenter, randomized, double-blind, placebo-controlled phase 3 study","volume":"42","author":"Y Yang","year":"2024","journal-title":"The Lancet Regional Health\u2014Western Pacific"},{"issue":"4","key":"pone.0305621.ref040","doi-asserted-by":"crossref","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","article-title":"Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial","volume":"159","author":"J Kremer","year":"2013","journal-title":"Ann Intern Med"},{"issue":"3","key":"pone.0305621.ref041","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/art.37816","article-title":"Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study.","volume":"65","author":"D van der Heijde","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"10055","key":"pone.0305621.ref042","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis.","volume":"388","author":"JS Smolen","year":"2016","journal-title":"Lancet"},{"issue":"5","key":"pone.0305621.ref043","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s40259-016-0190-5","article-title":"Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis.","volume":"30","author":"S Nakayamada","year":"2016","journal-title":"BioDrugs"},{"issue":"Suppl 1","key":"pone.0305621.ref044","doi-asserted-by":"crossref","first-page":"i27","DOI":"10.1093\/rheumatology\/key256","article-title":"Clinical efficacy of new JAK inhibitors under development. Just more of the same?","volume":"58","author":"R. Westhovens","year":"2019","journal-title":"Rheumatology (Oxford)."},{"key":"pone.0305621.ref045","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1146\/annurev.iy.13.040195.002101","article-title":"Signaling through the hematopoietic cytokine receptors","volume":"13","author":"JN Ihle","year":"1995","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"pone.0305621.ref046","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jphs.2016.12.001","article-title":"A novel JAK inhibitor, peficitinib, demonstrates potent efficacy in a rat adjuvant-induced arthritis model.","volume":"133","author":"M Ito","year":"2017","journal-title":"J Pharmacol Sci"},{"issue":"10","key":"pone.0305621.ref047","doi-asserted-by":"crossref","first-page":"666","DOI":"10.7326\/M15-2521","article-title":"Uncertainty in Treatment Rankings: Reanalysis of Network Meta-analyses of Randomized Trials","volume":"164","author":"L Trinquart","year":"2016","journal-title":"Ann Intern Med"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0305621","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T17:47:29Z","timestamp":1718992049000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0305621"}},"subtitle":[],"editor":[{"given":"Sadiq","family":"Umar","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,6,21]]},"references-count":47,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0305621","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,21]]}}}